HM
CLDI icon

Howard Marks’s Calidi Biotherapeutics CLDI Stock Holding History

Howard Marks’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-156
Closed -$2.98M – 382
2022
Q2 		$2.98M Hold
156
– – 0.03% 212
2022
Q1 		$2.97M Hold
156
– – 0.03% 211
2021
Q4 		$2.95M Buy
+156
New +$2.94M 0.03% 198

Other funds holding CLDI

DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
LSC
Logan Stone Capital Chicago, Illinois $473M AUM 0.79% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return

Howard Marks's CLDI Position: Q3 2022 in Review

Howard Marks sold out of Calidi Biotherapeutics (CLDI) in Q3 2022, closing a stake of 156 shares — an estimated $2.98M sold.

Howard Marks first reported a position in CLDI in Q4 2021 and held it in 3 quarters. The position peaked at $2.98M in Q2 2022. 20 funds tracked by Wall St. Rank hold CLDI as of Q3 2022.

  • Howard Marks reported no remaining Calidi Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Howard Marks sold 156 Calidi Biotherapeutics shares in Q3 2022, an estimated $2.98M.
  • Howard Marks first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 3 quarters.
  • Howard Marks's Calidi Biotherapeutics position peaked at $2.98M in Q2 2022.
  • 20 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2022.

Based on Oaktree Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.